Conduit Pharmaceuticals Inc., previously known as Murphy Canyon Acquisition Corp., has filed an amendment to Schedule 13G with the United States Securities and Exchange Commission (SEC), indicating a significant shareholding by a group of related entities. The filing, dated October 4, 2024, reveals that Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited, all registered in Guernsey, collectively hold 8,092,000 shares of Conduit Pharmaceuticals' common stock, representing 8.3% of the company. This stake includes both direct ownership and shares issuable upon the exercise of warrants. The entities have entered into a Joint Filing Agreement, suggesting a coordinated approach to their investment in Conduit Pharmaceuticals. The filing emphasizes that the shares were not acquired for the purpose of changing or influencing the control of the issuer.

Conduit Pharmaceuticals Inc., previously known as Murphy Canyon Acquisition Corp., has filed an amendment to Schedule 13G with the United States Securities and Exchange Commission (SEC), indicating a significant shareholding by a group of related entities. The filing, dated October 4, 2024, reveals that Nirland Limited, Stockton Limited, The Rowland Master Trust, and Dovet Limited, all registered in Guernsey, collectively hold 8,092,000 shares of Conduit Pharmaceuticals' common stock, representing 8.3% of the company. This stake includes both direct ownership and shares issuable upon the exercise of warrants. The entities have entered into a Joint Filing Agreement, suggesting a coordinated approach to their investment in Conduit Pharmaceuticals. The filing emphasizes that the shares were not acquired for the purpose of changing or influencing the control of the issuer.